Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2006, 52, 47-58

https://doi.org/10.14712/fb2006052030047

Immunological Profiles of Patients with Chronic Myeloid Leukaemia. I. State before the Start of Treatment

Zuzana Humlová1,2, H. Klamová3, I. Janatková1, P. Šandová1, I. Šterzl2, E. Sobotková4, E. Hamšíková4, C. Haškovec5, M. Písačka3, P. Cetkovský3, K. Michalová6, E. Faber7, Z. Heřmanová8, M. Ordeltová8, K. Roubalová9, Z. Roth10, Vladimír Vonka4

1Department of Clinical Biochemistry and Laboratory Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
2Department of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, and the General Teaching Hospital, Prague, Czech Republic
3Clinical Department, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
4Department of Experimental Virology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
5Department of Molecular Biology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
6Department of Cytogenetics, Institute of Haematology and Blood Transfusion, Prague, Czech Republic
7Department of Haemato-Oncology, The Teaching Hospital, Palacky University, Olomouc, Czech Republic
8Department of Immunology, The Teaching Hospital, Palacky University, Olomouc, Czech Republic
9Reference Laboratory for Herpesviruses, National Institute of Health, Prague, Czech Republic
10Department of Biostatistics, National Institute of Health, Prague, Czech Republic

Received May 2006
Accepted June 2006

References

1. Anand, M., Chodda, S. K., Parikh, P. M., Nadkarni, J. S. (1998) Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukaemia in different stages, and their role in prognosis. Hematol. Oncol. 16, 143-154. <https://doi.org/10.1002/(SICI)1099-1069(199812)16:4<143::AID-HON628>3.0.CO;2-U>
2. Anisimová, E., Prachová, E., Roubal, J., Vonka, V. (1984) Effect of a-butyrate and phorbol-ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch. Virol. 81, 223-227. <https://doi.org/10.1007/BF01309995>
3. Appel, S., Boehmler, A. M., Grunebach, F., Muller, M. R., Rupf, A., Weck, M. M., Hartmann, U., Reichardt, V. L., Kanz, L., Brummendorf, T. M., Brossart, P. (2004) Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cell. Blood 103, 538-544. <https://doi.org/10.1182/blood-2003-03-0975>
4. Burchert, A., Neubauer, A. (2005) Interferon α and T-cell responses in chronic myeloid leukaemia. Leuk. Lymphoma 46, 167-175. <https://doi.org/10.1080/10428190400012029>
5. Chen, X., Woiciechowsky, A., Raffegerst, S., Schendel, D., Kolb, H. J., Roskrow, M. (2000) Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br. J. Haematol. 111, 817-825.
6. Chiorean, E. G., Dylla, S. J., Olsen, K., Lenvik, T., Soignier, Y., Miller, J. S. (2003) BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). Blood 101, 3527-3533. <https://doi.org/10.1182/blood-2002-04-1172>
7. Cho, E. K., Heo, D. S., Seol, J. G., Seo, E. J., Chi, H. S., Kim, E. S., Lee, Y. Y., Kim, B. K., Kim, N. K. (2000) Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br. J. Haematol. 111, 216-222.
8. Chomczynski, P., Sacchi, N. (1987) Single-step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159. <https://doi.org/10.1016/0003-2697(87)90021-2>
9. Cramer, E., Auclair, C., Hakim, J., Feliu, E., Boucherot, J., Troube, J., Bernard, J. F., Bergogne, E., Boivin, P. (1977) Metabolic activity of phagocytosis granulocytes in chronic granulocytic leukaemia: ultrastructural observation of a degranulation effect. Blood 50, 93-106. <https://doi.org/10.1182/blood.V50.1.93.93>
10. Cross, N. C., Melo, J. V., Feng, L., Goldman, J. M. (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukaemia 8, 186-189.
11. Dacey, M. J., Callen, J. P. (2003) Hydroxyurea-induced dermatomyositis-like eruption. J. Am. Acad. Dermatol. 48, 439-441. <https://doi.org/10.1067/mjd.2003.74>
12. Dietz, A. B., Socan, L., Knutson, G. J., Bulur, P. A., Litzow, M. R., Vuk-Pavlovic, S. (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104, 1094-1099. <https://doi.org/10.1182/blood-2003-12-4266>
13. Du Clos, T. W., Mold, C. (2004) C-reactive protein. An activator of innate immunity and modulator of adaptive immunity. Immunol. Res. 30, 261-277. <https://doi.org/10.1385/IR:30:3:261>
14. DuVillard, L., Guiguet, M., Casasnovas, R. O., Caillot, D., Monnier-Zeller, V., Bernard, A., Guy, H., Solary, E. (1995) Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br. J. Haematol. 89, 243-249.
15. Ghalaut, V. S., Ghalaut, P. S., Karb, S. (1999) Immunological assessment in patients of leukaemia. Indian. J. Pathol. Microbiol. 42, 471-474.
16. Guc, D., Canpinar, H., Kucukaksu, C., Kansu, E. (2000) Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur. J. Haematol. 64, 3-9. <https://doi.org/10.1034/j.1600-0609.2000.80097.x>
17. Hamšíková, E., Ludvíková, V., Šmahel, M., Sapp, M., Vonka, V. (1998) Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int. J. Cancer 77, 689-694. <https://doi.org/10.1002/(SICI)1097-0215(19980831)77:5<689::AID-IJC5>3.0.CO;2-R>
18. Haškovec, C., Ponzetto, C., Polák, J., Mariano, D., Zemanová, Z., Serra, A., Michalová, K., Klamová, H., Čermák, J., Saglio, G. (1998) P230 BCR/ABL may be associated with an acute leukaemia phenotype. Br. J. Haematol. 103, 1104-1108. <https://doi.org/10.1046/j.1365-2141.1998.01098.x>
19. Hirano, T. (1992) Interleukin 6 and autoimmunity and plasma cell neoplasias. Res. Immunol. 143, 759-763. <https://doi.org/10.1016/0923-2494(92)80019-H>
20. Inoue, K., Sugiyama, H., Ogawa, H., Yamagami, T., Azuma, T., Oka, Y., Miwa, H., Kita, K., Hiraoka, A., Masaoka, T., Nasu, K., Kyo, T., Dohy, H., Hara, J., Kanamaru, A., Kishimoto, T. (1994) Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukaemia. Blood 84, 2672-2680. <https://doi.org/10.1182/blood.V84.8.2672.2672>
21. Ishii, N., Murakami, H., Matsushimi, T., Tamura, J., Sawamura, M., Morita, K., Karasawa, M., Naruse, T., Kubota, K., Tsuchiya, J., Kurosawa, M., Maeyama, K. (1995) Histamine excess symptoms in basophililic crisis of chronic myelogenous leukaemia. J. Med. 26, 235-240.
22. Jolliff, C. R., Cost, K. M., Stivrins, P. C., Grossman, P. P., Nolte, C. R., Franco, S. M., Fijan, K. J., Fletcher, L. L., Shriner, H. C. (1982) Reference intervals for serum IgG, IgA, IgM, C3 and C4 as determined by rate nephelometry. Clin. Chem. 28, 126-128. <https://doi.org/10.1093/clinchem/28.1.126>
23. Kiani, A., Habermann, I., Schake, K., Meubauer, A., Rogge, L., Ehninger, G. (2003) Normal intrinsic Th1/Th2 balance with chronic phase chronic myeloid leukaemia not treated with interferon-alpha or imatinib. Haematologica 88, 754-761.
24. Kleemann, R., Gervois, P. P., Verschuren, L., Staels, B., Princen, H. M., Kooistra, T. (2003) Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood 101, 545-551. <https://doi.org/10.1182/blood-2002-06-1762>
25. Kyriakou, D., Papadaki, H., Eliopoulos, A. G., Foudoulakis, A., Alexandrakis, M., Eliopoulos, G. D. (1997) Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int. J. Haematol. 66, 367-371. <https://doi.org/10.1016/S0925-5710(97)00055-8>
26. Le Coutre, P., Kreuzer, K. A., Na, I. K., Lupberger, J., Holdhoff, M., Appelt, C., Schwarz, M., Miller, C., Gambacorti-Passerini, C., Platzbacher, U., Bonnet, R., Ehninger, G., Schmidt, C. A. (2002) Determination of alpha-1 acid glycoprotein in patients with Ph1 chronic myeloid leukaemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis. 28, 75-85. <https://doi.org/10.1006/bcmd.2002.0493>
27. Mahmoud, F. A., Rivera, N. I. (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr. Oncol. Rep. 4, 250-255. <https://doi.org/10.1007/s11912-002-0023-1>
28. Marečková, H., Ravdan, A., Fučíková, T., Janatková, I. (2002) Detection of the production of intracellular cytokines by T lymphocytes using flow cytometry – methodologic problems. Epidemiol. Microbiol. Imunol. 51, 111-118.
29. Mellemkjaer, L., Hammarstrom, L., Andersen, V., Yuen, J., Heilmann, C., Barington, T., Bjorkander, J., Olsen, J. H. (2002) Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin. Exp. Immunol. 130, 495-500. <https://doi.org/10.1046/j.1365-2249.2002.02004.x>
30. Mellqvist, U. H., Hansson, M., Brune, M., Dahlgren, C., Hermodsson, S., Hellstrand, K. (2000) Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukaemia cells: role of reactive oxygen species and regulation by histamine. Blood 96, 1961-1968. <https://doi.org/10.1182/blood.V96.5.1961>
31. Minh, D. Q., Czink, E., Mod, A., Fust, G, Hollan, S. R. (1983) Serial complement measurements in patients with leukaemia. Clin. Lab. Haematol. 5, 23-24. <https://doi.org/10.1111/j.1365-2257.1983.tb00493.x>
32. Mitelman, F. (1995) An international System for Human Cytogenetic Nomenclature. Karger AG, Basel.
33. Nakajima, H., Zhao, R., Lund, T. C., Ward, J., Dolan, M., Hirsch, B., Miller, J. S. (2002) The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukaemia patients. J. Immunol. 168, 643-650. <https://doi.org/10.4049/jimmunol.168.2.643>
34. Pawelec, G., Rehbein, A., Schlotz, E., da Silva, P. (1996) Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol. Immunother. 42, 193-199. <https://doi.org/10.1007/s002620050270>
35. Pawelec, G., Schlotz, E., Rehbein, A. (1999) IFN-alpha regulates IL-10 production by CML cells in vitro. Cancer Immunol. Immunother. 48, 430-434. <https://doi.org/10.1007/s002620050619>
36. Pierson, B. A., Miller, J. S. (1997) The role of autologous natural killer cells in chronic myelogenous leukaemia Leuk. Lymphoma 27, 387-399. <https://doi.org/10.3109/10428199709058306>
37. Plummer, G. A. (1973) A review of the identification and titration of antibodies to herpes simplex virus type 1 and type 2 in human sera. Cancer Res. 33, 1469-1476.
38. Resnitzky, D., Tiefenbrun, N., Berissi, H., Kimchi, A. (1992) Interferons and interleukin-6 suppress phosphorylation of retinoblastoma protein in growth-sensitive haematopoietic cells. Proc. Natl. Acad. Sci. USA 89, 402-406. <https://doi.org/10.1073/pnas.89.1.402>
39. Reuben, J. M., Lee, B. N., Johnson, H., Fritsche, H., Kantarjian, H. M., Talpaz, M. (2000) Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukaemia in cytogenetic and haematologic remission with interferon-alpha. Clin. Cancer Res. 6, 1671-1677.
40. Roberts, W. L., Sedrick, R., Moulton, L., Spencer, A. (2000) Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Clin. Chem. 46, 461-468. <https://doi.org/10.1093/clinchem/46.4.461>
41. Roubalová, K., Roubal, J., Skopový, P., Fuèíková, T., Domorázková, E., Vonka, V. (1988) Antibody response to Epstein-Barr virus antigens in patients with chronic viral infection. J. Med. Virol. 25, 115-122. <https://doi.org/10.1002/jmv.1890250115>
42. Shackleford, M. D., McAlister, W. H. (1975) Primary immunodeficiency diseases and malignancy. Am. J. Roentgenol. Radium Ther. Nucl. Med. 123, 144-153. <https://doi.org/10.2214/ajr.123.1.144>
43. Solanki, R. L., Anand, V. K., Arora, H. L. (1990) Serum immunoglobulins in leukaemia and malignant lymphoma. J. Indian. Med. Assoc. 88, 305-307.
44. Steegmann, J. L., Requena, M. J., Martin-Regueira, P., de la Camara, R., Casado, F., Salvanes, F. R., FernandezRanada, J. M. (2003a) High incidence of autoimmune alterations in chronic myeloid leukaemia patients treated with interferon-alpha. Am. J. Hematol. 72, 170-176. <https://doi.org/10.1002/ajh.10282>
45. Steegmann, J. L., Moreno, G., Alaez, C., Granada, A., de la Camara, R., Arranz, E., Reino, F. G., Salvanes, F. R., Fernandez-Ranada, J. M., Munoz, C. (2003b) Chronic myeloid leukaemia patients resistant to or intolerant of interferon and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 88, 762-768.
46. Szalai, A. J. (2004) C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin. Dev. Immunol. 11, 221-226.
47. Tothova, E., Kafkova, A., Stecova, N., Fricova, M., Guman, T., Svorocova, E. (2002) Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukaemia. Neoplasma 49, 91-94.
48. Tsuda, H., Yamasaki, H. (2000) Type I and type II T cell profiles in chronic myelogenous leukaemia. Acta Haematol. 103, 96-101. <https://doi.org/10.1159/000041027>
49. Yamamura, M., Yamada, Y., Momita, S., Kamihira, S., Tomonaga, M. (1998) Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br. J. Haematol. 100, 129-134. <https://doi.org/10.1046/j.1365-2141.1998.00538.x>
50. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukaemia cells that is inhibited by interleukin-6. Nature 352, 345-347. <https://doi.org/10.1038/352345a0>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive